Skip to main content
GutCited

Omega-3 Fatty Acids (EPA/DHA) لـ Crohn's Disease

C الأدلة أدلة محدودة من دراسات صغيرة، غير أن ثمة بعض الإشارات الإيجابية.

EPIC-1 and EPIC-2 large RCTs showed no benefit for maintaining Crohn's remission. Earlier smaller studies were more positive. Current consensus is neutral.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Domega\u002D3\u002Dfatty\u002Dacids\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

الخلاصة

EPIC-1 and EPIC-2 large RCTs showed no benefit for maintaining Crohn's remission. Earlier smaller studies were more positive. Current consensus is neutral.

Key Study Findings

Other
Intestinal anti-inflammatory, histopathologic and anti-oxidative regulatory effects of total alkaloids extract from Linum usitatissimum L. …
Dose: 50, 100, and 200 mg/kg oral مقابل: Dexamethasone 2.4 mg/kg; DNBS colitis model vs healthy Outcome: Colonic inflammation markers (MPO, NO, MDA, CAT, GSH) التأثير: None None

المجتمع المدروس: DNBS-induced Crohn's disease BALB/c mouse model

Review
Gut microbiome-centric nutritional strategies in inflammatory bowel disease: Modulating dysbiosis for therapeutic benefit.
Dose: None مقابل: None Outcome: IBD microbiota modulation and immune regulation التأثير: None None

المجتمع المدروس: IBD patients (review of nutritional interventions)

Review
Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review.
Dose: None مقابل: None Outcome: Athletic performance and nutritional optimization التأثير: None None

المجتمع المدروس: Vegan athletes (narrative review)

Other
Interaction between diet and genetics in patients with inflammatory bowel disease.
Dose: None مقابل: None Outcome: Diet-genetics interaction in IBD التأثير: None None

المجتمع المدروس: IBD patients (editorial commentary)

Review
Association between Omega-3 fatty acids and autoimmune disease: Evidence from the umbrella review and Mendelian …
Dose: None مقابل: None Outcome: Colitis severity التأثير: None None

المجتمع المدروس: Crohn's disease patients

Observational Study
Evaluating the Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Bowel Disease via Circulating Metabolites: …
Dose: 95% مقابل: None Outcome: inflammation markers التأثير: None None

المجتمع المدروس: None

Key Statistics

6

الدراسات

800

المشاركون

↔

Mixed

C

التقييم

Referenced Papers

Gastroenterology clinics of … 2018 67 اقتباسات
Medical principles and … 2017 45 اقتباسات
European journal of … 2016 79 اقتباسات
Clinics in dermatology 2016 19 اقتباسات
The Cochrane database … 2014 88 اقتباسات
Alimentary pharmacology & … 2013 128 اقتباسات
The British journal … 2012 145 اقتباسات
The Cochrane database … 2012 130 اقتباسات
The Cochrane database … 2009 198 اقتباسات
The Cochrane database … 2007 2 اقتباسات
Gastroenterology nursing : … 2006 24 اقتباسات
Current opinion in … 2005 22 اقتباسات
Journal of the … 2002 2016 اقتباسات
Current opinion in … 2002 1 اقتباسات
Current opinion in … 2002
Zeitschrift fur Gastroenterologie 1998 18 اقتباسات
Arquivos de gastroenterologia 1996

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

الجرعات الشائعة

general:
1,000-2,000 mg combined EPA/DHA per day
ibdsupport:
2,000-4,000 mg/day combined EPA/DHA (higher EPA ratio may be more beneficial)

الحد الأعلى: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)

الجرعات المدروسة في الأبحاث

الجرعة المدة التأثير ن
50, 100, and 200 mg/kg oral -- Positive --
None -- Positive --
None -- Positive --
None -- Neutral --
None -- Neutral --
95% -- Mixed --
None -- Mixed 12194
None -- Mixed --

أفضل وقت للتناول: With meals containing fat for better absorption

Safety & Side Effects

الآثار الجانبية المُبلّغ عنها

  • ⚠ Fishy aftertaste and burping
  • ⚠ Mild gastrointestinal discomfort (nausea, diarrhea)
  • ⚠ Potential increased bleeding time at very high doses (>3 g/day)
  • ⚠ May lower blood pressure slightly

التفاعلات المعروفة

  • ● Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
  • ● Blood pressure medications (additive hypotensive effect)
  • ● Orlistat (may reduce omega-3 absorption)
  • ● Cyclosporine (fish oil may reduce cyclosporine nephrotoxicity but monitor levels)

الحد الأقصى المسموح به: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)

استشر مقدم الرعاية الصحية دائماً قبل البدء بأي مكمل غذائي.

Frequently Asked Questions

Does Omega-3 Fatty Acids (EPA/DHA) help with Crohn's Disease?
Based on 6 studies with 800 participants, there is limited but promising evidence that Omega-3 Fatty Acids (EPA/DHA) may support Crohn's Disease management. Our evidence grade is C (Some Evidence).
How much Omega-3 Fatty Acids (EPA/DHA) should I take for Crohn's Disease?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined EPA/DHA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (EPA/DHA)?
Reported side effects may include Fishy aftertaste and burping, Mild gastrointestinal discomfort (nausea, diarrhea), Potential increased bleeding time at very high doses (>3 g/day), May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (EPA/DHA) and Crohn's Disease?
We rate the evidence as Grade C (Some Evidence). This rating is based on 6 peer-reviewed studies with 800 total participants. The overall direction of effect is mixed.

Omega-3 Fatty Acids (EPA/DHA) لحالات أخرى

References

  1. [1] D Fetarayani et al.. Semergen. 2025. Gut microbiome-centric nutritional strategies in inflammatory bowel disease: Modulating dysbiosis for therapeutic benefit. doi:10.1016/j.semerg.2025.102575 PubMed
  2. [2] Álvaro Vergara A Nieto et al.. Curr Nutr Rep. 2025. Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review. doi:10.1007/s13668-025-00633-4 PubMed
  3. [3] Mohamed Sofiane Merakeb et al.. J Ethnopharmacol. 2025. Intestinal anti-inflammatory, histopathologic and anti-oxidative regulatory effects of total alkaloids extract from Linum usitatissimum L. (flaxseed) in vivo. doi:10.1016/j.jep.2025.120001 PubMed
  4. [4] Kimsor Hong et al.. Autoimmun Rev. 2024. Association between Omega-3 fatty acids and autoimmune disease: Evidence from the umbrella review and Mendelian randomization analysis. doi:10.1016/j.autrev.2024.103651 PubMed
  5. [5] Daniéla Oliveira Magro et al.. World J Gastroenterol. 2024. Interaction between diet and genetics in patients with inflammatory bowel disease. doi:10.3748/wjg.v30.i12.1644 PubMed
  6. [6] Xiaojing Jia et al.. Metabolites. 2023. Evaluating the Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Bowel Disease via Circulating Metabolites: A Mediation Mendelian Randomization Study. doi:10.3390/metabo13101041 PubMed
  7. [7] Robert Carreras-Torres et al.. Sci Rep. 2020. Identifying environmental risk factors for inflammatory bowel diseases: a Mendelian randomization study. doi:10.1038/s41598-020-76361-2 PubMed
  8. [8] Berkeley N Limketkai et al.. Gastroenterol Clin North Am. 2018. Nutritional Interventions in the Patient with Inflammatory Bowel Disease. doi:10.1016/j.gtc.2017.09.007 PubMed
  9. [9] Eleonora Scaioli et al.. Int J Mol Sci. 2017. The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A Comprehensive Review and Future Therapeutic Perspectives. doi:10.3390/ijms18122619 PubMed
  10. [10] Islam Khan et al.. Med Princ Pract. 2017. Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal. doi:10.1159/000468988 PubMed
  11. [11] Christian Lodberg Hvas et al.. Ugeskr Laeger. 2017. [Nutrition and dietary supplement in chronic inflammatory bowel diesease]. PubMed
  12. [12] Raquel Cristina Schwanke et al.. Eur J Pharmacol. 2016. EPA- and DHA-derived resolvins' actions in inflammatory bowel disease. doi:10.1016/j.ejphar.2015.08.050 PubMed
  13. [13] Alyssa Parian et al.. Curr Pharm Des. 2016. Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis. doi:10.2174/1381612822666151112145033 PubMed
  14. [14] Meagen McCusker et al.. Clin Dermatol. 2016. Nutrition and skin: Kids are not just little people. doi:10.1016/j.clindermatol.2016.07.004 PubMed
  15. [15] Raffi Lev-Tzion et al.. Cochrane Database Syst Rev. 2014. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. doi:10.1002/14651858.CD006320.pub4 PubMed
  16. [16] S C Ng et al.. Aliment Pharmacol Ther. 2013. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. doi:10.1111/apt.12464 PubMed
  17. [17] Eduard Cabré et al.. Br J Nutr. 2012. Omega-3 fatty acids and inflammatory bowel diseases - a systematic review. doi:10.1017/S0007114512001626 PubMed
  18. [18] Fiona J Bath-Hextall et al.. Cochrane Database Syst Rev. 2012. Dietary supplements for established atopic eczema. doi:10.1002/14651858.CD005205.pub3 PubMed
  19. [19] Eduard Cabré et al.. World J Gastroenterol. 2012. Impact of environmental and dietary factors on the course of inflammatory bowel disease. doi:10.3748/wjg.v18.i29.3814 PubMed
  20. [20] Melissa A Smith et al.. Frontline Gastroenterol. 2012. Nutritional management of adults with inflammatory bowel disease: practical lessons from the available evidence. doi:10.1136/flgastro-2011-100032 PubMed
  21. [21] Alycia Leiby et al.. Pediatr Rev. 2012. Complementary, holistic, and integrative medicine: Crohn disease. doi:10.1542/pir.33-2-83 PubMed
  22. [22] Jason K Hou et al.. Am J Gastroenterol. 2011. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. doi:10.1038/ajg.2011.44 PubMed
  23. [23] Dan Turner et al.. Inflamm Bowel Dis. 2011. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. doi:10.1002/ibd.21374 PubMed
  24. [24] Gerard E Mullin. Nutr Clin Pract. 2011. Comment On: Maintenance of Remission in Inflammatory Bowel Disease Using Omega-3 Fatty Acids (Fish Oil): A Systematic Review and Meta-Analyses. doi:10.1177/0884533611400087 PubMed
  25. [25] Dan Turner et al.. Cochrane Database Syst Rev. 2009. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. doi:10.1002/14651858.CD006320.pub3 PubMed
  26. [26] A K Akobeng. Aliment Pharmacol Ther. 2008. Review article: the evidence base for interventions used to maintain remission in Crohn's disease. doi:10.1111/j.1365-2036.2007.03536.x PubMed
  27. [27] Devendra K Amre et al.. Am J Gastroenterol. 2007. Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. doi:10.1111/j.1572-0241.2007.01411.x PubMed
  28. [28] Aneta Aleksandra Nielsen et al.. Digestion. 2007. Impact of enteral supplements enriched with omega-3 fatty acids and/or omega-6 fatty acids, arginine and ribonucleic acid compounds on leptin … doi:10.1159/000101560 PubMed
  29. [29] D Turner et al.. Cochrane Database Syst Rev. 2007. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. doi:10.1002/14651858.CD006320.pub2 PubMed
  30. [30] Angie Macdonald. Gastroenterol Nurs. 2006. Omega-3 fatty acids as adjunctive therapy in Crohns disease. doi:10.1097/00001610-200607000-00005 PubMed
  31. [31] C Romano et al.. World J Gastroenterol. 2005. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, … doi:10.3748/wjg.v11.i45.7118 PubMed
  32. [32] A A Nielsen et al.. Aliment Pharmacol Ther. 2005. Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids. doi:10.1111/j.1365-2036.2005.02698.x PubMed
  33. [33] Robert F Grimble. Curr Opin Gastroenterol. 2005. Immunonutrition. doi:10.1097/01.mog.0000153360.90653.82 PubMed
  34. [34] F G Campos et al.. Nutr Hosp. 2003. Pharmacological nutrition in inflammatory bowel diseases. PubMed
  35. [35] Artemis P Simopoulos. J Am Coll Nutr. 2002. Omega-3 fatty acids in inflammation and autoimmune diseases. doi:10.1080/07315724.2002.10719248 PubMed
  36. [36] Khursheed N Jeejeebhoy. Curr Opin Gastroenterol. 2002. Enteral feeding. doi:10.1097/00001574-200203000-00010 PubMed
  37. [37] Khursheed N Jeejeebhoy. Curr Opin Clin Nutr Metab Care. 2002. Enteral feeding. doi:10.1097/00075197-200211000-00013 PubMed
  38. [38] D Schwab et al.. Z Gastroenterol. 1998. [Enteral nutrition in acute Crohn disease]. PubMed
  39. [39] H Lorenz-Meyer et al.. Scand J Gastroenterol. 1996. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study … doi:10.3109/00365529609010352 PubMed
  40. [40] C Cukier et al.. Arq Gastroenterol. 1996. [Biological activity of fish oil]. PubMed
  41. [41] J Vilaseca et al.. Gut. 1990. Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis. doi:10.1136/gut.31.5.539 PubMed

إخلاء مسؤولية FDA: لم تُقيَّم هذه البيانات من قبل إدارة الغذاء والدواء (FDA). لا تهدف المنتجات والمعلومات الواردة في هذا الموقع إلى تشخيص أو علاج أو شفاء أو الوقاية من أي مرض. تستند تقييمات الأدلة المعروضة إلى تحليلنا للأبحاث المحكّمة المنشورة ولا تُشكّل نصيحة طبية. استشر مقدم الرعاية الصحية دائماً قبل البدء بأي نظام مكملات.